Protective effect of silymarin against chemical-induced cardiotoxicity

Document Type : Review Article


1 Targeted Drug Delivery Research Center, Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2 Pharmaceutical Research Center, Pharmacy School, Mashhad University of Medical Sciences, Mashhad, Iran


Cardiac disorders remain one of the most important causes of death in the world. Oxidative stress has been suggested as one of the molecular mechanisms involved in drug-induced cardiac toxicity. Recently, several natural products have been utilized in different studies with the aim to protect the progression of oxidative stress-induced cardiac disorders. There is a large body of evidence that administration of antioxidants may be useful in ameliorating cardiac toxicity. Silymarin, a polyphenolic flavonoid has been shown to have utility in several cardiovascular disorders. In this review, various studies in scientific databases regarding the preventive effects of silymarin against cardiotoxicity induced by chemicals were introduced. Although there are many studies representing the valuable effects of silymarin in different diseases, the number of researches relating to the possible cardiac protective effects of silymarin against drugs induced toxicity is rather limited. Results of these studies show that silymarin has a broad spectrum of cardiac protective activity against toxicity induced by some chemicals including metals, environmental pollutants, oxidative agents and anticancer drugs. Further studies are needed to establish the utility of silymarin in protection against cardiac toxicity.


1.Negi A, Kumar J, Luqman S, Shanker K, Gupta M, Khanuja S. Recent advances in plant hepatoprotectives: A chemical and biological profile of some important leads. Med Res Rev 2008; 28: 746-772.
2.Luper S. A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 1998; 3: 410-421.
3.Pepping J. Milk thistle: Silybum marianum, . Am J Health System Pharm 1999; 56: 1195-1197.
4.Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. Silymarin, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci 2011; 14: 308-317.
5.Dixit N, Baboota S, Kohli K, Ahmad S, Ali J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol 2007; 39: 172-179.
6.Karimi G, Hassanzadeh M, Mehri S. Protective effects of Silymarin against free radical-induced erythrocyte lysis, J Altern Complementary  Med. 2006; 3.
7.Nazemian F. Effect of silymarin administration on TNF-α serum concentration in peritoneal dialysis patients. Phytother Res 2010; 24:1654–1657.
8.Ramakrishnan G,  Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. cell prolif 2009; 42: 229-240.
9.Taghiabadi T, Imenshahidi M, Abnous K, Mosafa F, Sankian M, Karimi G. Protective Effect of Silymarin against Acrolein-Induced Cardiotoxicity in Mice. Evid Based Complementary Altern Med 2013; 2012: Article ID 352091.
10.Muthumani M, Milton Prabu S. Silibinin potentially attenuates arsenic-induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats. Cardiovasc Toxicol 2014; 14: 83-97.
11.Karimi G, Saradeghi Keisari M. Evaluation of antidepressant effect of ethanolic and aqueous extracts of Silybum marianum L. seed in mice. J Med Plants 2007; 6: 38-43.
12.Morishima C, Shuhart M, Wang CC, Paschal D, Apodaca M, Liu Y. Silymarin inhibits in vitro cell proliferation and cytokine production in hepatitis c virus infection. Gastroenterology 2010; 138: 671-681.
13.Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complementary Altern Med 2005a; 2: 383-386.
14.Karimi G, Fallah Huseini H, Ramezani M, Tahoonian Z. Protective effect of silybum marianum (l.) gaertn. seeds extract and silymarin against cisplatin-induced acute nephrotoxicity in rats. J Med Plants 2005b; 4: 42-45.
15.Chu S, Chiou H, Chen P, Yang S, Hsieh Y. Silybinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog 2004; 40:  143-149.
16.Kanter M, Meral I, Yener Z. Partial regeneration/ proliferation of the beta-cells in the islets of Langerhans by Nigella sativa L. in streptozotocin-induced diabetic rats. J Exp Med 2003; 201: 213-219.
17.Toklu H, Tunali-Akbay T, Erkanli G, Yuksel M, Ercan F, Sener G. Silymarin, the antioxidant component of silybum marianum, protects against burn-induced oxidative skin injury. Burns 2007; 33: 908-916.
18.Saller R, Melzer J, Reichling J, Brignoli R, Meier R. An updated systematic review of the pharmacology of silymarin. Forsch Komp Klas Nat 2007; 14: 70-80.
19.Fleming T. PDR for Herbal Medicines. New Jersy Medical Economics Company, 2000; 516-518
20.Kren V, Walterova D. Silybin and Silymarin,  New effects and applications . Biomed Papers 2005;  149: 29-41.
21.Rao P, Viswanath R. Cardioprotective activity of silymarin in ischemia-reperfusion-induced myo-cardial infarction in albino rats. Exp Clin Cardiol 2007; 12: 179-187.
22.Talha J, Priyanka M A A. Hypertension and herbal plants. Int Res J Pharm 2011; 2: 26-30.
23.Sinha M, Manna P, SIL P. Terminalia arjuna protects mouse hearts against sodium fluoride-induced oxidative stress. J Med Food 2008; 11:733-740.
24.Nabavi S, Moghaddam A, Setzer W, Mirzaei M. Effect of silymarin on sodium fluoride-induced toxicity and oxidative stress in rat cardiac tissues. Anais da Academia Brasileira de Ciências 2012; 84: 1121-1126.
25.Murphy C. G. Oudit. Iron-overload cardiomyo-pathy: Pathophysiology, diagnosis, and treatment. J Card Fail 2010; 16: 888-900.
26.Wang Y, Wu M, Al-Rousan R, Liu H, Fannin J, Paturi S. Iron-induced cardiac damage: Role of apoptosis and deferasirox intervention. J Pharmacol Exp Ther 2011; 336: 56-63.
27.Borsari M, Gabbi C, Ghelfi F, Grandi R, Saladini M, Severi S. Silybin, a new iron-chelating agent. J Inorg Biochem 2001; 85: 123-129.
28.Gharagozloo M, Khoshdel Z, Amirghofran Z. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: A comparison with desferrioxamine. Eur J Pharmacol 2008; 589: 1-7.
29.Najafzadeh H, Jalali M, Morovvati H, Taravati F. Comparison of the Prophylactic Effect of Silymarin and Deferoxamine on Iron Overload-Induced Hepatotoxicity in Rat. J Med Toxicol 2010; 6: 22-26.
30.Navidi-Shishaone M, Mohhebi S, Nematbakhsh M, Roozbehani S, Talebi A, Pezeshki Z, Eshraghi-Jazi F, Mazaheri S, Shirdavani S, Gharagozloo M, Alsaadat Moaeidi B. Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart  Iron Deposition in Male Iron Overload Rat Model. Int J Prev Med 2014; 5: 110-116.
31.Moon K, Guallar E, Navas–Acien A. Arsenic Exposure and Cardiovascular Disease: An Updated Systematic Review. Curr Atheroscler Rep 2012; 14: 542-555.
32.Manna P, Sinha MPS. Arsenic induced oxidative myocardial injury: Protective role of arjunolic acid. Arch Toxicol 2008; 82 :137-149.
33.Alamolhodaei NS, Shirani K, Karimi G. Arsenic cardiotoxicity: An overview. EnvToxicol Pharmacol 2015; 40: 1005-1014.
34.Yamauchi H, Aminaka Y, Yoshida K, Sun G, Pi J,  Waalkes M. Evaluation of DNA damage in patients with arsenic poisoning: Urinary 8-hydroxydeoxyguanine. Toxicol Appl Pharmacol 2004; 198: 291-296.
35.Dutta M, Ghosh A, Rangari V, Jain G, Khobragade S, Chattopadhyay A, Bhowmick D, Das T, Bandyopadhyay D. Silymarin protects against copper-ascorbate induced injury to goat cardiac mitochondria in vitro: involvement of antioxidant machnism. Int J Pharm Pharm Sci 2014; 6: 422-429.
36.Miltonprabu S, Thangapandiyan S. Epigallocatechin gallate potentially attenuates Fluoride induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats. J Trace Elem Med Biol 2015; 29: 321-335.
37.Shashi A, Thapar S. Histopathology of myocardial damage in experimental fluorosis in rabbits. Fluoride 2001; 34: 43-50.
38.Donmez N, Cinar A. Effects of chronic fluorosis on electrocardiogram in sheep. Biol Trace Elem Res 2003; 2 :115-122.
39.Nabavi S, Nabavi SF, Eslami S, Moghaddam A. In vivo protective effects of quercetin against sodium fluoride-induced oxidative stress in the hepatic tissue. Food ChemToxicol 2012; 132: 931-935.
40.Ma Y, Niu R, Sun Z, Wang J, Luo G, Zhang J, Wang J. Inflammatory responses induced by fluoride and arsenic at toxic concentration in rabbit aorta. Arch Toxicol  2012;  86: 849-856.
41.Diwan A, Dorn G. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology 2007; 22: 56-64.
42.Molkentin J, Dorn G. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001; 63: 391-426.
43.Bernardo B. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010; 128: 191-227.
44.Takimoto E, Kass D. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49: 241-248.
45.Anestopoulos I, Kavoa A, Tentesc I, Kortsarisc A, Panayiotidisd M, Lazoub A, Pappaa A. Silibinin protects H9c2 cardiac cells from oxidative stress and inhibits phenylephrine-induced hypertrophy: potential mechanisms. J Nut Biochem 2013; 24: 586-594.
46.Cieslak D, Lazou A. Regulation of BAD protein by PKA, PKCdelta and phosphatases in adult rat cardiac myocytes subjected to oxidative stress. . Mol Cells  2007; 24: 224-231.
47.Communal C. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the               β-adrenergic pathway. Circulation 1998; 98: 1329-1334.
48.Zhou B, Wu L, Li L, Tashiro S, Onodera S, Uchiumi  F, Ikejima T. Silibinin Protects Against Isoproterenol-Induced Rat Cardiac Myocyte Injury Through Mitochondrial Pathway After Up-regulation of SIRT1. J Pharmacol Sci 2006a; 102: 387-395.
49.Zhou B, Wu L, Tashiro S, Onodera S, Uchiumi F, Ikejima T. Silibinin Protects Rat Cardiac Myocyte from Isoproterenol-Induced DNA Damage Independent on Regulation of Cell Cycle. Biol Pharm Bull 2006b; 29: 1900-1905.
50.Zhou B, Wu L, Tashiro S, Onodera S, Uchiumi F, Ikejima T. Activation of extracellular signal-regulated kinase during silibininprotected, isoproterenol-induced apoptosis in rat cardiac myocytes is tyrosine kinase pathway-mediated and protein kinase C-dependent. Acta Pharmacol Sin 2007; 28: 803-810.
51.Faroon O, Roney N, Taylor J, Ashizawa A, Lumpkin M, Plewak D. Acrolein health effects. Toxicol Ind Health 2008; 24: 447-490.
52.Stevens J, Maier C. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol Nut Food Res 2008; 52: 7-25.
53.Raschi E, Vasina V, Ursino M. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 2010; 125: 196-218.
54.Ado R, de Keulenaer G, Leite-Moreira A, Brs-Silva C. Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. Rev Port Cardiol. 2013;32:395-409.
55.Blum R, Carter S. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med  1974; 80: 249-259.
56.El-Shitany N, El-Haggar S, El-desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food ChemToxicol 2008; 46: 2422–2428.
57.Chlopcikova S, Psotová P, Miketová P, Šimánek V. Chemoprotective Effect of Plant Phenolics against Anthracycline-induced Toxicity on Rat Cardiomyocytes. Part I. Silymarin and its Flavonolignans. Phytother Res 2004; 18: 107-110.
58.Cecen E, Dost T, Culhaci N, Karul A, Ergur B, Birincioglu M. Protective effects of silymarin against doxorubicin-induced toxicity. Asian Pacific J Cancer Prev 2011; 12: 2697-2704.
59.Psotová J, Chlopčíková S, Grambal F, Šimánek V, Ulrichová J. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res 2002; 16: S63-S67.
60.El-Awady E, Moustafa Y, Abo-Elmatty D, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol 2011; 650: 335-341.